Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, November 1st. Analysts expect Achillion Pharmaceuticals to post earnings of ($0.17) per share for the quarter.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.16). During the same period last year, the firm posted ($0.14) EPS. On average, analysts expect Achillion Pharmaceuticals to post $-0.69 EPS for the current fiscal year and $-0.74 EPS for the next fiscal year.

Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) opened at 3.83 on Wednesday. The firm’s market cap is $523.79 million. Achillion Pharmaceuticals, Inc. has a 52-week low of $3.15 and a 52-week high of $6.87. The company’s 50-day moving average price is $4.31 and its 200-day moving average price is $4.27.

COPYRIGHT VIOLATION WARNING: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/10/25/achillion-pharmaceuticals-inc-achn-set-to-announce-earnings-on-wednesday.html.

Several equities analysts have recently weighed in on ACHN shares. Maxim Group set a $7.00 price objective on Achillion Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. BidaskClub upgraded Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. Ladenburg Thalmann Financial Services decreased their price objective on Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating for the company in a report on Tuesday, September 12th. Zacks Investment Research upgraded Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. Finally, Robert W. Baird restated a “neutral” rating and issued a $4.00 price objective (down previously from $5.00) on shares of Achillion Pharmaceuticals in a report on Tuesday, September 12th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $6.75.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Earnings History for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.